TransMedics Group (1TMDX) Stock Overview
A commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
1TMDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TransMedics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$105.35 |
| 52 Week High | US$110.90 |
| 52 Week Low | US$92.44 |
| Beta | 2.05 |
| 1 Month Change | 12.55% |
| 3 Month Change | -4.18% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 27.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1TMDX | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -1.3% | -15.0% | 2.3% |
| 1Y | n/a | -36.8% | 30.6% |
Return vs Industry: Insufficient data to determine how 1TMDX performed against the Italian Medical Equipment industry.
Return vs Market: Insufficient data to determine how 1TMDX performed against the Italian Market.
Price Volatility
| 1TMDX volatility | |
|---|---|
| 1TMDX Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 4.3% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.7% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: 1TMDX's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1TMDX's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 728 | Waleed Hassanein | www.transmedics.com |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
TransMedics Group, Inc. Fundamentals Summary
| 1TMDX fundamental statistics | |
|---|---|
| Market cap | €3.61b |
| Earnings (TTM) | €79.16m |
| Revenue (TTM) | €488.54m |
Is 1TMDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1TMDX income statement (TTM) | |
|---|---|
| Revenue | US$566.35m |
| Cost of Revenue | US$224.95m |
| Gross Profit | US$341.41m |
| Other Expenses | US$249.64m |
| Earnings | US$91.77m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.69 |
| Gross Margin | 60.28% |
| Net Profit Margin | 16.20% |
| Debt/Equity Ratio | 144.1% |
How did 1TMDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/11 05:37 |
| End of Day Share Price | 2025/11/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TransMedics Group, Inc. is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| William Plovanic | Canaccord Genuity |
| Daniel Markowitz | Evercore ISI |